Verrica Pharmaceuticals/$VRCA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Ticker
$VRCA
Sector
Primary listing
Employees
76
Headquarters
Website
VRCA Metrics
BasicAdvanced
$82M
-
-$1.68
1.46
-
Price and volume
Market cap
$82M
Beta
1.46
52-week high
$9.82
52-week low
$3.28
Average daily volume
134K
Financial strength
Current ratio
2.588
Quick ratio
2.162
Long term debt to equity
3.577
Total debt to equity
6.592
Interest coverage (TTM)
-1.54%
Profitability
EBITDA (TTM)
-11.454
Gross margin (TTM)
65.44%
Net profit margin (TTM)
-50.27%
Operating margin (TTM)
-33.56%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
-14.74%
Return on equity (TTM)
-240.35%
Valuation
Price to revenue (TTM)
1.425
Price to book
3.3
Price to tangible book (TTM)
3.3
Price to free cash flow (TTM)
-2.877
Free cash flow yield (TTM)
-34.76%
Free cash flow per share (TTM)
-1.655
Growth
Revenue change (TTM)
370.22%
Earnings per share change (TTM)
-88.64%
3-year revenue growth (CAGR)
57.93%
3-year earnings per share growth (CAGR)
-38.35%
VRCA News
AllArticlesVideos
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm
Business Wire·2 weeks ago
VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
Business Wire·2 weeks ago
Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Verrica Pharmaceuticals stock?
Verrica Pharmaceuticals (VRCA) has a market cap of $82M as of March 31, 2026.
What is the P/E ratio for Verrica Pharmaceuticals stock?
The price to earnings (P/E) ratio for Verrica Pharmaceuticals (VRCA) stock is 0 as of March 31, 2026.
Does Verrica Pharmaceuticals stock pay dividends?
No, Verrica Pharmaceuticals (VRCA) stock does not pay dividends to its shareholders as of March 31, 2026.
When is the next Verrica Pharmaceuticals dividend payment date?
Verrica Pharmaceuticals (VRCA) stock does not pay dividends to its shareholders.
What is the beta indicator for Verrica Pharmaceuticals?
Verrica Pharmaceuticals (VRCA) has a beta rating of 1.46. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.